A biomedical grade conductive polymer aqueous dispersion, hydrogel and preparation method thereof
Through the combined template strategy of dextran sulfate and carboxymethyl chitosan, poly3,4-ethylenedioxythiophene aqueous dispersion with good water dispersion and conductivity were prepared, solving the existing conductive polymers in biology Poor water dispersion and acid doping problems in medicine have achieved improvements in biocompatibility and conductivity, and are suitable for the biomedical field.
Patent Information
- Application Number
- CN202211588403.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-12
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-12-12
AI Technical Summary
The existing conductive polymer aqueous dispersions have problems with apoptosis, oxidative stress and inflammatory responses caused by poor water dispersion and acid doping in the field of biomedical science, which affects its application in tissue engineering.
Poly3,4-ethylenedioxythiophene is prepared by oxidative polymerization by using dextran sulfate as a dispersion and doping template, and the electrostatic and hydrogen bond interactions of carboxymethyl chitosan are combined to form poly3, 4-Ethoxythiophene: (glucan sulfate/carboxymethylchitosan) aqueous dispersion, regulates particle size between 80-220 nm, and improves its stability and conductivity in water.
The good water dispersion and biocompatibility of conductive polymers are achieved, and the cell and tissue reactions caused by acid doping are reduced, providing a safe and effective biomedical grade conductive material suitable for biosensing and tissue engineering.
Smart Images

Figure CN115850726B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a biomedical-grade conductive polymer aqueous dispersion, a hydrogel and a preparation method thereof, and belongs to the field of functional materials. Background Art
[0002] Conductive polymers, as pioneering organic electronic conductors, have been deeply explored in a wide range of fields such as energy devices, bioelectronics, and biomedicine. Polyaniline, polypyrrole, polythiophene, and their derivatives are used to prepare tissue engineering scaffolds due to their good electroactivity and chemical modifiability. However, the hydrophobic conjugated structure makes it difficult for conductive polymers to be stably dispersed in water systems. In order to improve their water dispersibility and conductivity, acidic media and small molecule dopants are often added. The introduction of these acidic dopants is not conducive to their application in the biomedical field, and long-term implantation can cause severe cell apoptosis, oxidative stress, and inflammatory reactions. At present, a commercial conductive polymer aqueous dispersion, poly (3,4-ethylenedioxythiophene): polystyrene sulfonic acid (PEDOT:PSS), is widely used in the preparation of electronic devices such as light-emitting diodes, organic solar cells, and supercapacitors. In recent years, many researchers have also compounded PEDOT:PSS with biocompatible polymers to prepare conductive hydrogels for tissue engineering. However, high concentrations of poly (3,4-ethylenedioxythiophene): polystyrene sulfonic acid can cause adverse reactions in cells and tissues, which are caused by the acidity and degradation side effects of polystyrene sulfonic acid. Due to the problem of acidic doping, PEDOT:PSS can only be adjusted within a low concentration range to maintain considerable cell compatibility in conductive scaffolds for tissue engineering, which sacrifices its conductive properties and makes the conductive properties of the hydrogel not highly matched with the host tissue. Therefore, it is urgent to develop biocompatible dispersion and doping strategies to improve the water dispersibility and conductivity of poly (3,4-ethylenedioxythiophene) while improving its cell compatibility and tissue compatibility. Conductive polymer aqueous dispersions designed for biomedical applications will have great potential in biomedical fields such as biosensing, bioelectronics and tissue engineering. Summary of the invention
[0003] The purpose of the present invention is to overcome the defects of poor water dispersibility and poor acid-doped biocompatibility of commercial conductive polymers, and to provide a biomedical grade conductive polymer aqueous dispersion which is simple to prepare, stable in nature, safe and effective, and a preparation method thereof.
[0004] The technical solution of the present invention is as follows:
[0005] A biomedical conductive polymer aqueous dispersion; poly(3,4-ethylenedioxythiophene): dextran sulfate is prepared by oxidative polymerization using dextran sulfate as a dispersion and doping template, and the electrostatic and hydrogen bond interactions of carboxymethyl chitosan are used to further disperse and assemble the conductive polymer to form a poly(3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion. The particle size is controlled between 80-220 nm by regulating the content of its components. It has stable water dispersibility, good cell biocompatibility and tissue compatibility, and good conductivity.
[0006] Specifically, first, under the dispersion and doping of dextran sulfate (DSS), 3,4-ethylenedioxythiophene (EDOT) is polymerized in an oxidation reaction system to form poly (3,4-ethylenedioxythiophene: dextran sulfate) (PEDOT:DSS) ( Figure 1 ); PEDOT:DSS was further assembled in the presence of carboxymethyl chitosan with positively charged amino groups and negatively charged carboxyl groups, and the uniform dispersion and extensive interconnection of the conductive components were achieved by decoupling the hydrophobic interaction of poly (3,4-ethylenedioxythiophene) conjugates. PEDOT showed a clustered morphology in the aqueous dispersion system ( Figure 2 a), after the dual dispersion of DSS and CMCS, PEDOT presents a uniformly dispersed nanoparticle structure, and forms a nanoscale interconnected network through polymer template assembly ( Figure 2 b, c). Finally, a conductive polymer aqueous dispersion poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) (PEDOT: (DSS / CMCS)) with good conductivity, water dispersibility and biocompatibility was prepared. The sedimentation rate of PEDOT: (DSS / CMCS) under centrifugal conditions was less than 5% ( Figure 3 a), with a conductivity of 1.0 to 1.3 S / m for medical use ( Figure 3 b). Through cytotoxicity test, the aqueous dispersion is non-toxic to adipose-derived stem cells and maintains cell viability greater than 97% ( Figure 4 a). After 3 and 14 days of implantation in vivo, the aqueous dispersion did not cause inflammatory reactions such as neutrophil aggregation, and the positive expression rate of Ly-6G was less than 0.7% ( Figure 4 b). The present invention uses PEDOT: (DSS / CMCS) aqueous dispersion and aldehyde-modified dextran to prepare a conductive hydrogel, which can inhibit ventricular remodeling and restore cardiac beating function in myocardial repair ( Figure 5 a,b).
[0007] The technical solution of the present invention is as follows:
[0008] A biomedical conductive polymer aqueous dispersion; the conductive polymer aqueous dispersion is composed of poly (3,4-ethylenedioxythiophene), xyloglucan sulfate and carboxymethyl chitosan; wherein the components and mass contents are as follows:
[0009] Poly(3,4-ethylenedioxythiophene) 0.4-3%,
[0010] Xyloglucan sulfate 0.6-3%,
[0011] Carboxymethyl chitosan 2-8%,
[0012] The balance is water.
[0013] The water dispersion has a particle size of 80-220 nm and presents a nano-micelle-like structure.
[0014] The preparation method of the biomedical grade conductive polymer aqueous dispersion of the present invention comprises the following steps:
[0015] (1) weighing dextran sulfate (DSS) and adding it into water to prepare a DSS solution with a mass concentration of 0.8-3.1%, and then dropwise adding 3,4-ethylenedioxythiophene (EDOT) therein, wherein the mass concentration of EDOT is 32-226 μmol / L; mechanically stirring in an ice-water bath under nitrogen protection for 0.5-1 hour to obtain an EDOT / DSS mixed solution;
[0016] (2) adding an ammonium persulfate solution to the mixed solution obtained in step (1) to a final concentration of 0.03-0.3 mmol / L; stirring for 5-20 minutes, adding a ferrous sulfate solution, and controlling the final mass concentration of ferrous sulfate to be 1.6-5 μmol / L; stirring for 24-72 hours, transferring the mixture to a cellulose dialysis bag, dialyzing with deionized water for 2-6 days, changing the water every 6 hours, and freeze-drying to obtain poly (3,4-ethylenedioxythiophene): dextran sulfate powder (PEDOT:DSS);
[0017] (3) The PEDOT:DSS composite powder obtained in step (2) is placed in a carboxymethyl chitosan solution with a mass concentration of 2-8%, and the mass concentration of PEDOT:DSS is controlled at 1-6%; ultrasonic dispersion and magnetic stirring are performed for 3-12 hours to obtain a poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion PEDOT: (DSS / CMCS).
[0018] The conductive hydrogel prepared by the biomedical conductive polymer aqueous dispersion of the present invention comprises 2-4% PEDOT: (DSS / CMCS) dispersion, 2-4% aldehyde-dextran (ODex), and the remaining component is water.
[0019] The method for preparing the conductive hydrogel of the present invention comprises the following steps:
[0020] (1) First, dextran is dissolved in water by magnetic stirring; then, sodium periodate solution is added to the dextran solution; the mixed solution is stirred for 2-6 hours at room temperature in the dark; then, ethylene glycol is added to terminate the reaction, and the mixture is transferred to a cellulose dialysis bag, and dialyzed with deionized water in the dark for 2-6 days, with the water changed every 6 hours, and aldehyde dextran (ODex) is obtained after freeze drying;
[0021] (2) Dissolve ODex in PBS buffer at room temperature with stirring to obtain an ODex solution with a mass fraction of 4-8%; uniformly mix the ODex solution and a PEDOT:(DSS / CMCS) aqueous dispersion with a mass fraction of 4-8% in a volume ratio of 1:3-3:1 to prepare a PEDOT:(DSS / CMCS) / ODex hydrogel.
[0022] In the step (1), preferably, the mass concentration of dextran is 50-100 g / L; and a sodium periodate solution is added to the dextran solution, wherein the sodium periodate content is 0.02-0.1 mol / L.
[0023] In the step (1), preferably, the concentration of added ethylene glycol is 1.3-7.7 mol / L; and the reaction is carried out for 1-4 hours.
[0024] In the step (2), the aqueous dispersion is preferably uniformly mixed through a medical tee.
[0025] The conductive hydrogel is an injectable hydrogel.
[0026] The conductive hydrogel is used in myocardial tissue engineering, neural tissue engineering or skin tissue engineering.
[0027] The biomedical grade PEDOT:(DSS / CMCS) aqueous dispersion obtained by the present invention has the following characteristics: good water dispersibility, and after centrifugation at a speed of 1500 rpm for 10-60 minutes, its sedimentation rate is less than 5%.
[0028] The biomedical grade PEDOT: (DSS / CMCS) aqueous dispersion obtained by the present invention avoids acidic doping, and the pH of the aqueous dispersion is about 7.4. It also has good electrical conductivity, with a conductivity of 0.8 to 1.3 S / m.
[0029] The injectable conductive hydrogel prepared by the invention has good biocompatibility and tissue compatibility, does not cause inflammatory reactions such as neutrophil aggregation after being implanted in the body, and the positive expression rate of Ly-6G is less than 0.7%.
[0030] The injectable conductive hydrogel prepared by the present invention can be used in myocardial tissue engineering, neural tissue engineering, skin tissue engineering and the like.
[0031] Compared with the existing commercial conductive polymer aqueous dispersion poly (3,4-ethylenedioxythiophene): polystyrene sulfonic acid), the present invention has the following beneficial effects: the multi-level template doping strategy of anionic polysaccharides and carboxymethyl chitosan improves the dispersibility of conductive polymers in physiological media, overcoming the defect of poly (3,4-ethylenedioxythiophene): polystyrene sulfonic acid that relies on acidic doping. The prepared poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) has good water dispersibility to facilitate integration with medical manufacturing technology ( Figure 3 a) with adjustable conductivity of 0.8-1.3S / m to meet the needs of bioelectronics and tissue engineering ( Figure 3 b). Compared with commercial PEDOT:PSS, poly(3,4-ethylenedioxythiophene):(dextran sulfate / carboxymethyl chitosan) has high cell compatibility (cell viability greater than 97%, Figure 4 a) and low inflammatory response (the positive expression rate of Ly-6G was less than 0.7%, Figure 4 b). BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 : Schematic diagram of the preparation of poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion;
[0033] Figure 2 : Transmission electron microscopy photos of conductive polymers. a) Transmission electron microscopy photo of poly (3,4-ethylenedioxythiophene); b) Transmission electron microscopy photo of poly (3,4-ethylenedioxythiophene): dextran sulfate; c) Transmission electron microscopy photo of poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan);
[0034] Figure 3 :Tests on the physical and chemical properties of conductive polymers. a) Water dispersibility of conductive polymers; b) Conductivity of conductive polymers;
[0035] Figure 4 :Biocompatibility of conductive polymers. a) Cell viability of conductive polymers; b) Neutrophil expression rate of conductive polymers;
[0036] Figure 5 :Myocardial repair effect of conductive polymer hydrogel a) Masson's trichrome staining; b) echocardiography. DETAILED DESCRIPTION
[0037] The technical solution of the present invention is further described below in conjunction with specific examples. The reagents used in the following examples mainly include the following: water, 3,4-ethylenedioxythiophene, dextran sulfate, carboxymethyl chitosan, ammonium persulfate, ferrous sulfate heptahydrate, mesenchymal stem cells, and umbilical vein endothelial cells.
[0038] A biomedical grade conductive polymer aqueous dispersion, which consists of poly (3,4-ethylenedioxythiophene) (PEDOT), xyloglucan sulfate (DSS) and carboxymethyl chitosan (CMCS), wherein the mass content of PEDOT is 0.4-3%, the mass content of DSS is 0.6-3%, the mass content of CMCS is 2-8%, and the balance is water. The formed aqueous dispersion presents a nano-micelle-like structure, and the particle size is controlled between 80-220nm by regulating the content of its components.
[0039] The method for preparing the biomedical grade conductive polymer aqueous dispersion of the present invention comprises the following steps:
[0040] (1) weighing dextran sulfate (DSS) and adding it into water to prepare a DSS solution with a mass concentration of 0.8-3.1%, and then dropwise adding 3,4-ethylenedioxythiophene (EDOT) therein, wherein the mass concentration of EDOT is 32-226 μmol / L; mechanically stirring in an ice-water bath under nitrogen protection for 0.5-1 hour to obtain an EDOT / DSS mixed solution;
[0041] (2) adding an ammonium persulfate solution to the mixed solution obtained in step (1) to a final concentration of 0.03-0.3 mmol / L; stirring for 5-20 minutes, adding a ferrous sulfate solution, and controlling the final mass concentration of ferrous sulfate to be 1.6-5 μmol / L; stirring for 24-72 hours, transferring the mixture to a cellulose dialysis bag, dialyzing with deionized water for 2-6 days, changing the water every 6 hours, and freeze-drying to obtain poly (3,4-ethylenedioxythiophene): dextran sulfate powder (PEDOT:DSS);
[0042] (3) The PEDOT:DSS composite powder obtained in step (2) is placed in a carboxymethyl chitosan solution with a mass concentration of 2-8%, and the mass concentration of PEDOT:DSS is controlled at 1-6%; ultrasonic dispersion and magnetic stirring are performed for 3-12 hours to obtain a poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion PEDOT: (DSS / CMCS).
[0043] The biomedical grade PEDOT:(DSS / CMCS) aqueous dispersion obtained by the present invention can be used to prepare an injectable conductive hydrogel for tissue engineering through a Schiff base reaction, and the composition thereof comprises 2-4% PEDOT:(DSS / CMCS) dispersion, 2-4% aldehyde-dextran (ODex), and the remaining component is water. The preparation method thereof comprises the following steps:
[0044] (1) First, dextran is dissolved in water by magnetic stirring for 30 minutes, and its mass concentration is 50-100 g / L. Then, sodium periodate solution is added to the dextran solution, and its final molar concentration is 0.02-0.1 mol / L. The mixed solution is stirred for 2-6 hours at room temperature in the dark. Subsequently, 5-30 mL of ethylene glycol is added to terminate the reaction. After 2 hours, the mixture is transferred to a cellulose dialysis bag and dialyzed with deionized water in the dark for 2-6 days, with the water changed every 6 hours, and ODex is obtained after freeze-drying.
[0045] (2) ODex was dissolved in PBS buffer at room temperature by stirring to prepare an ODex solution with a mass fraction of 4-8%. The ODex solution and the PEDOT:(DSS / CMCS) aqueous dispersion with a mass fraction of 4-8% were uniformly mixed at a volume ratio of 1:3-3:1 through a medical tee to prepare a PEDOT:(DSS / CMCS) / ODex hydrogel. Due to the dynamic Schiff base cross-linking reaction, the hydrogel has a dual injectable mechanism of shear thinning and in situ gelation.
[0046] Embodiment 1:
[0047] (1) 0.8 g of dextran sulfate was added to a container, and 25 mL of water and 600 μL of 3,4-ethylenedioxythiophene were added in sequence; the mass concentration of dextran sulfate was 0.8%, and the mass concentration of 3,4-ethylenedioxythiophene was 226 μmol / L; the mixture was mechanically stirred in an ice-water bath under nitrogen protection to obtain a mixed solution;
[0048] (2) adding 10 mL of 1.2 mmol / L ammonium persulfate solution to the mixed solution obtained in step (1); stirring for 10 minutes; adding 5 mL of 12.8 μmol / L ferrous sulfate solution; the concentrations of ammonium persulfate and ferrous sulfate in the final mixed solution are 0.3 mmol / L and 40 μmol / L, respectively; stirring for 72 hours; after the reaction is completed, transferring the product to a cellulose dialysis bag, dialyzing with deionized water for 6 days, changing the water every 6 hours, and freeze-drying to obtain poly (3,4-ethylenedioxythiophene): dextran sulfate powder;
[0049] (3) 0.6 g of the poly (3,4-ethylenedioxythiophene): dextran sulfate powder obtained in step (2) was ultrasonically dispersed in 9.4 mL of 8 wt% carboxymethyl chitosan solution and magnetically stirred for 12 hours to obtain a poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion, wherein the mass fraction of poly (3,4-ethylenedioxythiophene) is 3%, the mass fraction of dextran sulfate is 3%, and the mass fraction of carboxymethyl chitosan is 8%.
[0050] Using DSS as template, ammonium persulfate as oxidant, and ferrous sulfate as reductant, 3,4-ethylenedioxythiophene undergoes oxidative polymerization in aqueous solution to produce PEDOT:DSS. The PEDOT:DSS powder can be redispersed in carboxymethyl chitosan solution by ultrasonic dispersion to prepare conductive polymer aqueous dispersion PEDOT:(DSS / CMCS)( Figure 1 ). PEDOT presents aggregated morphology in water dispersion system ( Figure 2 a), after the dual dispersion of DSS and CMCS, PEDOT presents a uniformly dispersed nanoparticle structure, and forms a nanoscale interconnected network through polymer template assembly ( Figure 2 b, c). PEDOT:(DSS / CMCS) has significantly improved water dispersibility compared to PEDOT and PEDOT:DSS, and the sedimentation rate is less than 5% under 1500rpm centrifugal conditions ( Figure 3 a). PEDOT: (DSS / CMCS) has a conductivity of 1.21S / m ( Figure 3 a). Compared with the commercial control PEDOT:PSS, PEDOT:(DSS / CMCS) aqueous dispersion was non-toxic to adipose-derived stem cells and maintained cell viability greater than 97% ( Figure 4 a). PEDOT:(DSS / CMCS) aqueous dispersion has obvious biocompatibility due to the commercial PEDOT:PSS product. After 3 and 14 days of implantation in vivo, it did not cause inflammatory reactions such as neutrophil aggregation, and the positive expression rate of Ly-6G was less than 0.7% ( Figure 4 b).
[0051] Embodiment 2:
[0052] (1) 0.2 g of dextran sulfate was added to a container, and 25 mL of water and 85 μL of 3,4-ethylenedioxythiophene were added in sequence; the mass concentration of dextran sulfate was 0.8%, and the mass concentration of 3,4-ethylenedioxythiophene was 32 μmol / L; the mixture was mechanically stirred in an ice water bath under nitrogen protection to obtain a mixed solution;
[0053] (2) adding 10 mL of 0.12 mmol / L ammonium persulfate solution to the mixed solution obtained in step (1); stirring for 10 minutes; adding 5 mL of 12.8 μmol / L ferrous sulfate solution; the concentrations of ammonium persulfate and ferrous sulfate in the final mixed solution are 0.03 mmol / L and 1.6 μmol / L, respectively; stirring for 24 hours; after the reaction is completed, transferring the product to a cellulose dialysis bag, dialyzing with deionized water for 2 days, changing the water every 6 hours, and freeze-drying to obtain poly (3,4-ethylenedioxythiophene): dextran sulfate powder;
[0054] (3) 0.1 g of the poly (3,4-ethylenedioxythiophene): dextran sulfate powder obtained in step (2) was ultrasonically dispersed in 9.9 mL of a 2 wt% carboxymethyl chitosan solution and magnetically stirred for 3 hours to obtain a poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion, wherein the mass fraction of poly (3,4-ethylenedioxythiophene) was 0.4%, the mass fraction of dextran sulfate was 0.6%, and the mass fraction of carboxymethyl chitosan was 2%. The conductivity of PEDOT: (DSS / CMCS) was 1.01 S / m ( Figure 3 a).
[0055] Embodiment 3:
[0056] (1) 0.4 g of dextran sulfate was added to a container, and 25 mL of water and 200 μL of 3,4-ethylenedioxythiophene were added in sequence; the mass concentration of dextran sulfate was 1.6%, and the mass concentration of 3,4-ethylenedioxythiophene was 75 μmol / L; the mixture was mechanically stirred in an ice-water bath under nitrogen protection to obtain a mixed solution;
[0057] (2) adding 10 mL of 0.4 mmol / L ammonium persulfate solution to the mixed solution obtained in step (1); stirring for 20 minutes; adding 5 mL of 16 μmol / L ferrous sulfate solution; the concentrations of ammonium sulfate and ferrous sulfate in the final mixed solution are 0.1 mmol / L and 2 μmol / L, respectively; stirring for 48 hours; after the reaction is completed, transferring the product to a cellulose dialysis bag, dialyzing with deionized water for 4 days, changing the water every 6 hours, and freeze-drying to obtain poly (3,4-ethylenedioxythiophene): dextran sulfate powder;
[0058] (3) 0.2 g of the composite powder obtained in step (2) was ultrasonically dispersed in 9.9 mL of 4 wt% carboxymethyl chitosan solution and magnetically stirred for 6 hours to obtain a poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion having a conductivity of 1.14 S / m ( Figure 3 a). The mass fraction of poly (3,4-ethylenedioxythiophene) is 0.8%, the mass fraction of dextran sulfate is 1.2%, and the mass fraction of carboxymethyl chitosan is 2%.
[0059] Embodiment 4:
[0060] (1) 0.6 g of dextran sulfate was added to a container, and 25 mL of water and 400 μL of 3,4-ethylenedioxythiophene were added in sequence; the mass concentration of dextran sulfate was 2.3%, and the mass concentration of 3,4-ethylenedioxythiophene was 151 μmol / L; the mixture was mechanically stirred in an ice-water bath under nitrogen protection to obtain a mixed solution;
[0061] (2) adding 10 mL of 0.8 mmol / L ammonium persulfate solution to the mixed solution obtained in step (1); stirring for 5 minutes; adding 5 mL of 24 μmol / L ferrous sulfate solution; the concentrations of ammonium sulfate and ferrous sulfate in the final mixed solution are 0.2 mmol / L and 3 μmol / L, respectively; stirring for 72 hours; after the reaction is completed, transferring the product to a cellulose dialysis bag, dialyzing with deionized water for 5 days, changing the water every 6 hours, and freeze-drying to obtain poly (3,4-ethylenedioxythiophene): dextran sulfate powder;
[0062] (3) 0.4 g of the composite powder obtained in step (2) was ultrasonically dispersed in 9.75 mL of a 6 wt% carboxymethyl chitosan solution and magnetically stirred for 8 hours to obtain a poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion having a conductivity of 1.30 S / m ( Figure 3 a). The mass fraction of poly (3,4-ethylenedioxythiophene) is 2%, the mass fraction of dextran sulfate is 2%, and the mass fraction of carboxymethyl chitosan is 6%.
[0063] Embodiment 5:
[0064] (1) 0.7 g of dextran sulfate was added to a container, and 25 mL of water and 500 μL of 3,4-ethylenedioxythiophene were added in sequence; the mass concentration of dextran sulfate was 2.7%, and the mass concentration of 3,4-ethylenedioxythiophene was 188 μmol / L; the mixture was mechanically stirred in an ice-water bath under nitrogen protection to obtain a mixed solution;
[0065] (2) adding 10 mL of 1 mmol / L ammonium persulfate solution to the mixed solution obtained in step (1); stirring for 10 minutes; adding 5 mL of 32 mmol / L ferrous sulfate solution; the concentrations of ammonium sulfate and ferrous sulfate in the final mixed solution are 0.25 mmol / L and 4 μmol / L, respectively; stirring for 60 hours; after the reaction is completed, transferring the product to a cellulose dialysis bag, dialyzing with deionized water for 6 days, changing the water every 6 hours, and freeze-drying to obtain poly (3,4-ethylenedioxythiophene): dextran sulfate powder;
[0066] (3) 0.5 g of the composite powder obtained in step (2) was ultrasonically dispersed in 9.7 mL of a 7 wt% carboxymethyl chitosan solution and magnetically stirred for 10 hours to obtain a poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion, wherein the mass fraction of poly (3,4-ethylenedioxythiophene) was 2.5%, the mass fraction of dextran sulfate was 2.5%, and the mass fraction of carboxymethyl chitosan was 7%.
[0067] Embodiment 6:
[0068] (1) First, 5 g of dextran was dissolved in 50 mL of water by magnetic stirring, and its mass concentration was 100 g / L. Then, 20 mL of 0.35 mol / L sodium periodate solution was added to the dextran solution, and the molar concentration of sodium periodate in its final mixed solution was 0.1 mol / L. The mixed solution was stirred for 6 hours under light-proof and room temperature conditions. Subsequently, 30 mL of ethylene glycol was added to terminate the reaction, and its molar concentration was 7.7 mol / L. After 4 hours of reaction, the mixture was transferred to a cellulose dialysis bag and dialyzed with deionized water under light-proof conditions for 6 days, with the water changed every 6 hours. After freeze-drying, aldehyde-modified dextran (ODex) was obtained.
[0069] (2) 0.8 g of ODex was dissolved in 9.2 mL of PBS buffer at room temperature by stirring to prepare an 8% ODex solution. 0.5 mL of ODex solution and 0.5 mL of 8% PEDOT:(DSS / CMCS) aqueous dispersion were uniformly mixed through a medical tee at a volume ratio of 1:1 to prepare an injectable PEDOT:(DSS / CMCS) / ODex hydrogel. The composition contained 4% PEDOT:(DSS / CMCS) dispersion, 4% aldehyde-dextran (ODex), and the remaining components were water.
[0070] Embodiment 7:
[0071] (1) First, 2.5 g of dextran was dissolved in 50 mL of water by magnetic stirring, and its mass concentration was 50 g / L. Then, 20 mL of 0.07 mol / L sodium periodate solution was added to the dextran solution, and the molar concentration of sodium periodate in its final mixed solution was 0.02 mol / L. The mixed solution was stirred for 2 hours under light-proof and room temperature conditions. Subsequently, 5 mL of ethylene glycol was added to terminate the reaction, and its molar concentration was 1.3 mol / L. After reacting for 1 hour, the mixture was transferred to a cellulose dialysis bag and dialyzed with deionized water under light-proof conditions for 2 days, with the water changed every 6 hours, and ODex was obtained after freeze-drying.
[0072] (2) 0.4 g of ODex was dissolved in 9.6 mL of PBS buffer at room temperature by stirring to prepare a 4% ODex solution. 0.3 mL of ODex solution and 0.9 mL of 4% PEDOT:(DSS / CMCS) aqueous dispersion were uniformly mixed through a medical tee at a volume ratio of 1:3 to prepare an injectable PEDOT:(DSS / CMCS) / ODex hydrogel. The composition contained 3% PEDOT:(DSS / CMCS) dispersion, 1% aldehyde-dextran (ODex), and the remaining components were water.
[0073] Embodiment 8:
[0074] (1) First, 3.75 g of dextran was dissolved in 50 mL of water by magnetic stirring, and its mass concentration was 75 g / L. Then, 20 mL of 0.21 mol / L sodium periodate solution was added to the dextran solution, and the molar concentration of sodium periodate in its final mixed solution was 0.06 mol / L. The mixed solution was stirred for 4 hours under light-proof and room temperature conditions. Subsequently, 20 mL of ethylene glycol was added to terminate the reaction, and its molar concentration was 5.1 mol / L. After reacting for 2 hours, the mixture was transferred to a cellulose dialysis bag and dialyzed with deionized water under light-proof conditions for 4 days, with the water changed every 6 hours, and ODex was obtained after freeze-drying.
[0075] (2) 0.6 g of ODex was dissolved in 9.4 mL of PBS buffer at room temperature with stirring to prepare a 6% ODex solution. 0.9 mL of ODex solution and 0.3 mL of 6% PEDOT:(DSS / CMCS) aqueous dispersion were uniformly mixed through a medical tee at a volume ratio of 3:1 to prepare an injectable PEDOT:(DSS / CMCS) / ODex hydrogel. The composition contained 1.5% PEDOT:(DSS / CMCS) dispersion, 4.5% aldehyde-dextran (ODex), and the remaining components were water.
[0076] Embodiment 9:
[0077] The myocardial ischemic injury model was established by ligating the left anterior descending branch of the rat heart. Tissue pallor in the ligated area and typical ST elevation on the electrocardiogram were used to determine myocardial infarction. Inguinal adipose tissue was extracted from rats (4 weeks old, about 80 g), and the adipose tissue was digested with pancreatic enzyme and collagenase to extract adipose-derived mesenchymal stem cells. Mesenchymal stem cells (10 6 ) were resuspended in 50 μL ODex solution, then stored in a refrigerator at 4°C and used for surgical treatment. 50 μL of ODex solution containing mesenchymal stem cells was evenly mixed with 50 μL PEDOT: (DSS / CMCS) aqueous dispersion through a medical three-way pipe and injected into four locations of the pale infarct area on the myocardial tissue, with 25 μL PEDOT: (DSS / CMCS) / ODex hydrogel injected at each location. Figure 5 a shows the myocardial repair effect of conductive polymer hydrogel combined with mesenchymal stem cells, which can effectively reduce the infarct area and increase the wall thickness of the left ventricle. Figure 5 bEchocardiography was used to evaluate that conductive polymer hydrogel combined with mesenchymal stem cells can improve the blood pumping capacity of myocardial tissue during relaxation and contraction, and significantly improve pathological myocardial structure and function.
[0078] Embodiment 10:
[0079] Myocardial ischemic injury model was established by ligating the left anterior descending branch of the rat heart. Tissue pallor in the ligated area and typical ST elevation on the electrocardiogram were used to determine myocardial infarction. Mesenchymal stem cells (10 6 ) and umbilical vein endothelial cells (10 6 ) were resuspended in 60 μL ODex solution, then stored in a 4°C refrigerator and used for surgical treatment. 30 μL of ODex solution containing mesenchymal stem cells was evenly mixed with 60 μL PEDOT: (DSS / CMCS) aqueous dispersion through a medical three-way pipe to prepare 120 μL PEDOT: (DSS / CMCS) / ODex hydrogel, which was injected into four locations of the pale infarct area on the myocardial tissue, with 30 μL PEDOT: (DSS / CMCS) / ODex hydrogel injected at each location.
[0080] The technical solutions disclosed and proposed by the present invention can be realized by those skilled in the art by referring to the contents of this article and appropriately changing the conditions, routes and other links. Although the methods and preparation techniques of the present invention have been described through preferred embodiments, relevant technicians can obviously modify or re-combine the methods and technical routes described herein without departing from the content, spirit and scope of the present invention to realize the final preparation technology. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the spirit, scope and content of the present invention.
Claims
1. A biomedical conductive polymer aqueous dispersion; It is characterized in that The conductive polymer aqueous dispersion is composed of poly 3,4-ethylenedioxythiophene, xyloglucan sulfate and carboxymethyl chitosan; wherein the components and their mass contents are as follows: Poly(3,4-ethylenedioxythiophene) 0.4-3%, Xyloglucan sulfate 0.6-3%, Carboxymethyl chitosan 2−8%, The balance is water; The water dispersion has a particle size of 80-220 nm and presents a nano-micelle-like structure.
2. The method for preparing the biomedical grade conductive polymer aqueous dispersion according to claim 1, Its characteristics are: The steps include: (1) Dextran sulfate DSS was weighed and added into water to prepare a DSS solution with a mass concentration of 0.8-3.1%, and then 3,4-ethylenedioxythiophene EDOT was added dropwise therein, wherein the mass concentration of EDOT was 32-226 μmol / L; the mixture was mechanically stirred in an ice-water bath under nitrogen protection for 0.5-1 h to obtain an EDOT / DSS mixed solution; (2) Add ammonium persulfate solution to the mixed solution obtained in step (1) to a final concentration of 0.03-0.3 mmol / L; after stirring for 5-20 minutes, add ferrous sulfate solution to a final mass concentration of ferrous sulfate of 1.6-5 μmol / L; after stirring for 24-72 hours, transfer the mixture to a cellulose dialysis bag, dialyze with deionized water for 2-6 days, change the water every 6 hours, and obtain poly (3, 4-ethylenedioxythiophene): dextran sulfate powder (PEDOT:DSS) after freeze drying; (3) The PEDOT:DSS composite powder prepared in step (2) is placed in a carboxymethyl chitosan solution with a mass concentration of 2-8%, and the mass concentration of PEDOT:DSS is controlled at 1-6%; ultrasonic dispersion and magnetic stirring are performed for 3-12 hours to obtain poly (3,4-ethylenedioxythiophene): (dextran sulfate / carboxymethyl chitosan) aqueous dispersion PEDOT: (DSS / CMCS).
3. A conductive hydrogel prepared from the biomedical conductive polymer aqueous dispersion according to claim 1, Its characteristics are: The composition contained 2−4% PEDOT:(DSS / CMCS) dispersion, 2−4% aldehyde-modified dextran ODex, and the remainder was water.
4. The method for preparing the conductive hydrogel according to claim 3, Its characteristics are: The following steps are involved: (1) First, dextran is dissolved in water by magnetic stirring; Then, sodium periodate solution was added to the dextran solution; the mixed solution was stirred for 2-6 hours at room temperature in the dark; then, ethylene glycol was added to terminate the reaction, and the mixture was transferred to a cellulose dialysis bag and dialyzed with deionized water in the dark for 2-6 days, with the water changed every 6 hours, and the aldehyde dextran ODex was obtained after freeze drying; (2) Dissolve ODex in PBS buffer at room temperature by stirring to obtain a 4-8% ODex solution; uniformly mix the ODex solution and a 4-8% PEDOT:(DSS / CMCS) aqueous dispersion in a volume ratio of 1:3-3:1 to prepare a PEDOT:(DSS / CMCS) / ODex hydrogel.
5. The preparation method according to claim 4, Its characteristics are: In step (1), the mass concentration of dextran is 50-100 g / L; a sodium periodate solution is added to the dextran solution, wherein the sodium periodate content is 0.02-0.1 mol / L.
6. The preparation method according to claim 4, Its characteristics are: In step (1), ethylene glycol is added at a concentration of 1.3-7.7 mol / L; the reaction is carried out for 1-4 hours.
7. The preparation method according to claim 4, Its characteristics are: In step (2), the ODex solution and the aqueous dispersion are uniformly mixed through a medical tee.
8. The conductive hydrogel according to claim 3, Its characteristics are: The hydrogel is an injectable hydrogel.
9. The conductive hydrogel according to claim 3, Its characteristics are: Used in myocardial tissue engineering, neural tissue engineering or skin tissue engineering.
